BOSTON PHARMA HAS RECEIVED THE VIETNAM PHARMACEUTICAL STAR AWARD ASSERTING ROLE AND POSITION IN THE VIETNAMESE PHARMACEUTICAL MARKET

On the evening of May 17, 2024, at the Hanoi Opera House, the Vietnam Drug Administration and Health & Lifestyle Newspaper held the 2nd Award Ceremony for the title "Vietnam Pharmaceutical Star."

This event is part of the implementation plan for Phase II of the "Vietnamese People Prioritize Using Vietnamese Medicines" project by the Ministry of Health, in response to the campaign initiated by the Politburo.

The credibility of the program is endorsed by the Drug Administration of Vietnam - Ministry of Health, Boston Pharma proudly being selected as one of the 18 pharmaceutical manufacturing enterprises to receive the title of "Vietnam Pharmaceutical Star" for the second time in 2023. Additionally, two of the company's products, Nexipraz 40[1] and Bostogel[2], also received this title.

Representing Boston Pharma, Mr. Lê Ngọc Trình - Deputy General Director of the company, received the commemorative award at the ceremony.

The "Vietnam Pharmaceutical Star" title is awarded by the Ministry of Health to recognize and honor domestic pharmaceutical manufacturing enterprises with many effective therapeutic products, a large market presence, trusted by the public, and products originating in Vietnam that have been practically used and proven effective in disease prevention and treatment.

This achievement reaffirms the role and mission of Boston Pharma in the journey to protect and care for the health of the Vietnamese people.

Among hundreds of enterprises and pharmaceutical that submitted registration documents for participation, the selection council chose 18 enterprises and 68 outstanding pharmaceutical products to be awarded the title of "Vietnam Pharmaceutical Star" for the second time.

Both Nexipraz 40 and Bostogel products of Boston Pharma were voted for the award.

To achieve both of these titles, Boston Pharma had to go through a selection process with “strict” requirements from a team of experts and managers with prestige, and high professional qualifications, to attain these titles, Boston Pharma had to undergo a rigorous selection process with stringent requirements set by a team of esteemed experts and managers who possess high professional qualifications and a deep understanding of the pharmaceutical industry and clinical treatment. The Chairman of the Council is Associate Professor Dr. Le Van Truyen, a senior expert in Pharmacy and a former Deputy Minister of Health, and a deep understanding of the pharmaceutical industry as well as the field of clinical treatment.

According to Associate Professor, Dr. Le Van Truyen, the criteria for selecting pharmaceutical manufacturing enterprises to receive the title of "Vietnamese Pharmaceutical Star" include 3 criteria: Quality criteria (meeting GMP standards, no violations in the field of quality...), innovation, and creativity criteria (organization of research and development activities 'R&D', number of staff participating in research and development activities and trial production, qualifications of staff in research and development activities, investment costs for research and development activities and trial production...), production and business capacity (the process of establishment and operation of the enterprise, revenue in 3 consecutive years (2021-2023), business efficiency expressed by profit margin, number of products winning bids to supply to medical facilities, the proportion of prescription drugs in total products, distribution network, fulfillment of tax obligations...).

Boston Pharma is honored to receive the "Vietnam Pharmaceutical Star" title for the second time.

To surpass hundreds of other outstanding candidates in this award ceremony, Boston Pharma has continuously promoted investment in developing a manufacturing plant meeting EU-GMP and WHO-GMP standards. In addition, the company also focuses on developing a highly specialized workforce, proficient in operating and managing modern equipment.

All of the company's investment activities aim to bring quality products to the market at reasonable treatment costs, which is in line with the implementation plan of Phase II of the "Vietnamese People Prioritize Using Vietnamese Medicines" project by the Ministry of Health.

By simultaneously achieving the "Vietnam Pharmaceutical Star" title in both the enterprise and product categories, Boston Pharma has affirmed its reputation, quality, and position in the domestic pharmaceutical manufacturing market, aiming to become one of the "Top 10 best pharmaceutical manufacturing plants in Vietnam."

-----------------

[1] Nexipraz 40: contains the active ingredient of Esomeprazole 40mg and is used to treat Gastroesophageal Reflux Disease (GERD). It is also used in combination with antibiotics to eradicate Helicobacter pylori, helping to heal and prevent the recurrence of gastric and duodenal ulcers caused by this bacterium. Nexipraz 40 is effective in healing stomach ulcers caused by NSAID use and preventing such ulcers in at-risk patients. It is also prescribed for long-term treatment to prevent rebleeding from gastric and duodenal ulcers after intravenous treatment and for treating Zollinger-Ellison syndrome.

[2] Bostogel: product of the "National Key Scientific Research Program for the Development of Pharmaceutical Technology until 2020" led by Professor Le Minh Tri. It combines three active ingredients: Aluminum hydroxide, Magnesium hydroxide, and Simethicone. Bostogel is indicated to relieve symptoms of indigestion, heartburn, and bloating.